Status:
UNKNOWN
New Biomarkers for Diagnosis and Follow-up of Patients With LRBA or CTLA4 Deficiencies
Lead Sponsor:
Marmara University
Collaborating Sponsors:
The Scientific and Technological Research Council of Turkey
Conditions:
LRBA Deficiency
CTLA4 Haploinsufficiency
Eligibility:
All Genders
1-60 years
Brief Summary
Primary immune deficiencies (PID) are a group of chronic diseases characterized by recurrent infections. Apart from recurrent infections, in some of PIDs autoimmunity, allergy or malignancy could be a...
Detailed Description
Lipopolysaccharide-responsive beige-like anchor (LRBA) and cytotoxic T lymphocyte protein-4 (CTLA-4) deficiencies are primary immunodeficiency characterized by recurrent sinopulmonary infections with ...
Eligibility Criteria
Inclusion
- Patients diagnosed with LRBA and CTLA4 deficiencies and eligible for the study
- Patients accept consent to participate in this study and followed prospectively on abatacept treatment.
Exclusion
- History of hypersensitivity to abatacept
- History of acquired immunodeficiency diseases like HIV
- EBV viremia during the study screening
- Documented malignancy
- Current active infectious disease (bacterial or fungal) like tuberculosis
- Chronic hepatitis B or hepatitis C infections
Key Trial Info
Start Date :
January 15 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 15 2023
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04377867
Start Date
January 15 2020
End Date
January 15 2023
Last Update
May 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Marmara University
Istanbul, Pendik, Turkey (Türkiye), 34903